ReviewInternal medicine (Tokyo, Japan)2018
Diabetic Nephropathy: A Comparison of the Clinical and Pathological Features between the CKD Risk Classification and the Classification of Diabetic Nephropathy 2014 in Japan.
Review in Internal medicine (Tokyo, Japan), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 28 citations in OpenAlex.
- Erythropoiesis-stimulating agent resistance is associated with diabetic kidney disease but not with diabetes: a post hoc analysis of the BRIGHTEN study.Clinical and experimental nephrology · 2026Observational
- Comparing the Validity of Three Methods for Identifying Impaired Awareness of Hypoglycemia in Predicting Severe Hypoglycemia in Adults with Type 1 Diabetes Mellitus: The PR-IAH Study.Internal medicine (Tokyo, Japan) · 2026Article
- Trimethylamine N-Oxide Combined with Phenylacetylglutamine as Potential Biomarkers for Diabetic Kidney Disease.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Article
- Deep learning-based histopathological assessment of tubulo-interstitial injury in chronic kidney diseases.Communications medicine · 2025Article
- Article
- Lysozyme promotes renal fibrosis through the JAK/STAT3 signal pathway in diabetic nephropathy.Archives of medical science : AMS · 2024Article
- Urinary orosomucoid and retinol binding protein levels as early diagnostic markers for diabetic kidney Disease.BMC nephrology · 2023Article
- To Use or Not to Use a Self-monitoring of Blood Glucose System? Real-world Flash Glucose Monitoring Patterns Using a Cluster Analysis of the FGM-Japan Study.Internal medicine (Tokyo, Japan) · 2023Article
- Protective and risk factors of impaired awareness of hypoglycemia in patients with type 1 diabetes: a cross-sectional analysis of baseline data from the PR-IAH study.Diabetology & metabolic syndrome · 2023Article
- Factors associated with hemoglobin glycation index in adults with type 1 diabetes mellitus: The FGM-Japan study.Journal of diabetes investigation · 2023Article
- Association between thyroid hormones and diabetic kidney disease in Chinese adults.BMC endocrine disorders · 2023Article
- Association of Impaired Awareness of Hypoglycemia with Driving Safety and Hypoglycemia Problem-solving Abilities among Patients with Type 1 Diabetes in Japan: The PR-IAH Study.Internal medicine (Tokyo, Japan) · 2023Article
- Novel glucose-responsive nanoparticles based on p-hydroxyphenethyl anisate and 3-acrylamidophenylboronic acid reduce blood glucose and ameliorate diabetic nephropathy.Materials today. Bio · 2022Article
- Protective Effect of Adalimumab on Diabetic Nephropathy by Regulating TNF-α Signal Pathway.Iranian journal of public health · 2021Article
- Genetics Variants in the Epoxygenase Pathway of Arachidonic Metabolism Are Associated with Eicosanoids Levels and the Risk of Diabetic Nephropathy.Journal of clinical medicine · 2021Article
- The Role of Vascular Lesions in Diabetes Across a Spectrum of Clinical Kidney Disease.Kidney international reports · 2021Article
- The Discordance Between the Renal Histopathology and Clinical Presentation of Diabetic Nephropathy Calls for Novel Approaches for the Prediction and Monitoring of Kidney Failure in Diabetes.Kidney international reports · 2021Article
- Stimulation TcPO2 Testing Improves Diagnosis of Peripheral Arterial Disease in Patients With Diabetic Foot.Frontiers in endocrinology · 2021Article
- MiR-92b-3p is Induced by Advanced Glycation End Products and Involved in the Pathogenesis of Diabetic Nephropathy.Evidence-based complementary and alternative medicine : eCAM · 2020Article
- Association between Oral Health Status and Diabetic Nephropathy-Related Indices in Japanese Middle-Aged Men.Journal of diabetes research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic kidney disease is the main cause of end-stage kidney disease. However, the clinical manifestations of diabetic kidney disease are diverse. Therefore, the clinical classification of diabetic kidney disease is clinically important and valuable. In Japan, two clinical staging systems divided by the estimated glomerular filtration rate (eGFR) and albuminuria can be used for diabetic kidney disease: the chronic kidney disease (CKD) risk classification and the Japanese classification of diabetic nephropathy. The Japanese classification of diabetic nephropathy and the CKD risk classification are similar; however, these two classification systems show different frequencies of outcomes. For example, the frequency of the kidney outcomes in stage 4 of the Japanese classification of diabetic nephropathy was found to be higher than that in the red stage of the CKD risk classification (composite kidney events: stage 4=32.0/100 person-years, red =14.5/100 person-years). However, there were no marked differences in the speed or rate of decline in the kidney function (speed: stage 4=6.8 mL/min/1.73 m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.